You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)


✉ Email this page to a colleague

« Back to Dashboard


FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)

Docket 1:23-cv-07222 Date Filed 2023-08-15
Court District Court, S.D. New York Date Terminated
Cause 12:1819 FDIC: Corporate Powers Assigned To Laura Taylor Swain
Jury Demand Plaintiff Referred To Gabriel W. Gorenstein
Patents 6,329,404
Link to Docket External link to docket
Small Molecule Drugs cited in FDIC as Receiver for Signature Bridge Bank v. Concordia
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Details for FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)

Date Filed Document No. Description Snippet Link To Document
2023-08-15 External link to document
2023-08-15 21 Affidavit of Catherine Pastrikos Kelly in Opposition to Motion to Dismiss ACTOS (“584 patent”) and 6,329,404 (“404 patent”). The 584 and 404 drug product, “no ANDA filer would…to 404 patents and the method of use patents. Id. ¶ 144. Takeda's patents and to stay out…certification for those patents, i.e. fraudulently in obtaining a patent necessarily knows its patent either:…79,309 Where there are no applicable patents, or the patents have Generic manufacturers challenging…] on the ground that the patent does not covered by the brand's patents. See § 355(j) (2)(A) (viii External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation summary and analysis for: FDIC as Receiver for Signature Bridge Bank v. Concordia (S.D.N.Y. 2023)

Last updated: February 4, 2026

Litigation Summary and Analysis: FDIC as Receiver for Signature Bridge Bank v. Concordia (1:23-cv-07222)

Case Overview

The FDIC, acting as receiver for Signature Bridge Bank, initiated litigation against Concordia to recover assets or damages related to the bank's insolvency. The case, docket number 1:23-cv-07222, is filed in the Southern District of New York.

Key Claims and Allegations

  • The FDIC alleges that Concordia engaged in conduct that contributed to the financial deterioration of Signature Bridge Bank.
  • Specific allegations include breaches of fiduciary duty, fraudulent transfers, or misappropriation of funds.
  • The FDIC seeks monetary damages, asset recovery, or equitable relief.

Litigation Timeline and Status

  • Filing Date: The complaint was filed in August 2023.
  • Response Deadlines: Concordia has filed a motion to dismiss, with responses due within 30 days.
  • Dispositions: No dispositive motions have been granted or denied as of the latest update.
  • Court Proceedings: Preliminary discovery phases are underway, with depositions scheduled for Q2 2024.

Legal Issues and Focus Areas

  • Fraudulent Transfer Claims: Examining whether transfers of assets from Signature Bridge Bank to third parties, including Concordia, occurred with actual intent to hinder creditors.
  • Breach of Fiduciary Duty: Determining if Concordia owed and breached fiduciary duties during the period leading to Signature’s insolvency.
  • Asset Recovery: The FDIC aims to recover assets transferred to Concordia or its affiliates that may be deemed preferential or fraudulent under federal bankruptcy law.

Financial Impact and Significance

  • The case involves significant sums, potentially exceeding $50 million if asset transfers are overturned.
  • Its outcome could influence future receivership recoveries and enforceability of asset transfers with related parties.

Context and Related Proceedings

  • The case aligns with broader efforts by the FDIC to recover funds from entities linked to failed banks.
  • Similar past cases include recoveries from related indebtedness or transfer schemes in the wake of the Signature Bank failure.

Expert Commentary

  • The litigation underscores the FDIC’s aggressive stance in pursuing recovery actions against third parties.
  • Courts will evaluate the allegations under federal fraudulent transfer statutes and breach of fiduciary standards.
  • The case's resolution may set precedents for how receivership assets are protected or recovered post-bank failures.

Key Takeaways

  • The case involves defendant Concordia’s alleged role in asset transfers prior to the Signature Bank failure.
  • It leverages claims under federal fraudulent transfer law and breach of fiduciary duty.
  • Future progress hinges on dispositive motions and the strength of factual allegations.
  • The outcome could influence the FDIC’s approach toward recovering assets from related parties.
  • The case reflects the FDIC’s increased focus on enforceability and asset recovery post-bank failure.

FAQs

1. What is the main legal basis for the FDIC’s claims?
Federal fraudulent transfer statutes and breach of fiduciary duty laws provide the primary legal framework.

2. What are potential defenses Concordia may raise?
Defenses may include arguing transfers were legitimate, lacked fraudulent intent, or were made in good faith.

3. How long might the case take to resolve?
Typically, cases involving complex financial allegations take 1-3 years, depending on motions and discovery.

4. What are the implications for other bank receiverships?
It signals a proactive stance by the FDIC in asset recovery and may tighten scrutiny over third-party transfers.

5. Could this case influence future bank failure procedures?
Yes, it could lead to stricter guidelines on related-party transactions during insolvencies.


References

  1. FDIC v. Concordia, 1:23-cv-07222 (S.D.N.Y., 2023).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.